Cross presentation

Baltimore D (1988) Gene therapy. Intracellular immunization. Nature 335 395-396 Basta S, Stoessel R, Easier M, van den Broek M, Groettrup M (2005) Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 175 796-805 Baum C (2007) Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 14 337-342... 

Shen H, Ackerman AL, Cody V et al (2006) Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117 78-88... 

Fig. 1 K5. Top The complete graph on five vertices (left) and one-crossing presentation (right). Bottom Classical representations of K5 and the molecule made by Kuck and Schuster in 1988 [13], which has the same topology as K5...

Dendritic cells (DCs) can present tumor peptides via a pathway called cross-presentation antigens derived from tumor cells are captured by DCs, and are processed for presentation by MHC class I molecules. Antigens are transferred from tumor cells as intact proteins or proteasome substrates, not as peptides [296,297]. 

Tumor eells ean also present by themselves new MHC elass I-restricted peptides by cross-presentation, a feature believed to be unique of dendritic cells. A peptide derived from secreted matrix metalloproteinase-2 (MMP-2) is presented by melanoma cells, and the presentation is dependent on the enzyme secretion in the extracellular space, followed by uptake of exogenous MMP-2 through endocytosis mediated by integrin avPs. The process involves transfer of MMP-2 from the endocytic compartment to the cytosol and processing by the proteasome, because presentation of this peptide was blocked by proteasome inhibitors [298]. 

Chhabra A, Mehrotra S, Chakraborty N G, et al. (2004). Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur. J. Immunol. 34 2824-2833. 

Committee for Veterinary Medicinal Products (CVMP) 203, 204 complement activation 270, 273 complex PK/PD model 169 Contract Research Organisations (CROs) 129 Coomassie 49 copegus 136 Coptis japonica 29 copyright 187 corapporteur 204 com 37 COS-1 260 cosmetics 206 Creutzfeld-Jacob 120 Crohn s disease 132 crop cultivation 35 cross-presentation 82 cross-reactivity 106 CSF 225 CVM 207 cydohexamide 13 cydosporin 25 cydosporine A 12 cystic fibrosis 183, 250 cytochrome P450 17, 151... 

Heath, W.R., and Carbone, F.R. (2001) Cross-Presentation, Dendritic Cells, Tolerance and Immunity, Anna. Rev. Immunol. 19.41-64. 

Burgdorf, S., Scholz, C., Kautz, A., Tampe, R., Kurts, C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 9, 558-566 (2008)... 

Joffre, O.P., Segura, E., Savina, A., Amigorena, S. Cross-presentation by dendritic cells. Nature Reviews Immunology 12, 557-569 (2012)... 

Renaudet O, Dasgupta G, Bettahi I et al (2010) Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS One 5 ell216... 

---